Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. H.U. Group Holdings, Inc.
  6. News
  7. Summary
    4544   JP3822000000


SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Miraca unit seeks approval for Japan's first coronavirus antigen tests

04/27/2020 | 11:40am EDT

Fujirebio, a subsidiary of Japanese diagnostics and laboratory testing service provider Miraca Holdings, applied on Monday for government approval for Japan's first antigen coronavirus testing kits, a health ministry official said.

Japan's sole official test for coronavirus diagnosis is a polymerase chain reaction, or PCR, test. Antigen tests can be conducted more quickly, in about half an hour, potentially making virus tests more accessible to the public if approved.

The application will be fast-tracked, the official said.

"We usually aim to complete our review for approval within a year. But we will tackle this one as swiftly as possible," Takuma Kato, deputy director of the ministry's tuberculosis and infectious diseases control division, told Reuters.

Approval will likely be issued by the end of May, Kyodo news agency said, without citing sources.

There has been widespread criticism that phone lines for public health centres, tasked with conducting screening for PCR test candidates, are always busy and test results are slow to come by.

Critics say the low rate of testing in Japan has made it difficult to trace the new coronavirus, which can cause the COVID-19 respiratory disease, as it spreads and that this has led to a series of in-hospital infections, crippling some facilities.

Japan conducted about 52,000 PCR tests in March, or just 16% of the number carried out in South Korea, according to data from Oxford University.

A Miraca Holdings spokeswoman confirmed Fujirebio had filed for government approval but declined to give details, saying an official announcement would be made soon.

An antigen test targets the virus's protein to establish whether a person has the disease. An antibody test is used to detect those who have been infected with the virus and therefore had immunity.

Japan had reported 13,613 coronavirus infections as of late Monday evening, with 394 deaths, public broadcaster NHK said.

By Kiyoshi Takenaka

ę Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
H.U. GROUP HOLDINGS, INC. 0.96% 2930 End-of-day quote.5.43%
LETS HOLDINGS GROUP CO., LTD. 1.29% 7.05 End-of-day quote.-9.38%
LOOK HOLDINGS INCORPORATED -4.06% 1513 End-of-day quote.58.10%
All news about H.U. GROUP HOLDINGS, INC.
05/19H Uá : Notice Regarding Recording of Extraordinary Loss (Business Restructuring ..
05/19H Uá : Notice Regarding Revision of Dividend Forecast (Commemorative Dividend)
04/30H Uá : Notice Regarding the Occurrence of a Loss on Valuation of Shares of Subsi..
04/25H Uá : Notice Regarding Change (Retirement) of Representative Executive Officer
04/25H Uá : Appointment of Directors and Executive Officers of the Company and its Ma..
03/31H Uá : Announcement of Transfer of Non-Current Assets and Posting of Extraordina..
03/30H.U. GROUP HOLDINGS, INC. : Ex-dividend day for final dividend
02/24H Uá : Integrated Report 2020
2020CENTOGENE Ná : Fujirebio Europe and CENTOGENE Enter Partnership to Provide Rapid..
2020MIRACA HOLDINGS INC. : Ex-dividend day for interim dividend
More news
Sales 2021 223 B 2 031 M 2 031 M
Net income 2021 17 254 M 157 M 157 M
Net Debt 2021 41 096 M 374 M 374 M
P/E ratio 2021 9,68x
Yield 2021 5,09%
Capitalization 167 B 1 522 M 1 523 M
EV / Sales 2021 0,93x
EV / Sales 2022 0,91x
Nbr of Employees 5 968
Free-Float 99,1%
Duration : Period :
H.U. Group Holdings, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends H.U. GROUP HOLDINGS, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 5
Average target price 3 600,00 JPY
Last Close Price 2 930,00 JPY
Spread / Highest target 57,0%
Spread / Average Target 22,9%
Spread / Lowest Target 2,39%
EPS Revisions
Managers and Directors
Shigekazu Takeuchi President & Director
Naoki Kitamura Chief Financial Officer & Director
Hiroaki Kimura Head-Information Technology & Investor Relations
Kazuya Omi Executive Officer, Head-Research & Development
Ryoji Itoh Independent Outside Director
Sector and Competitors